Skip to main content

7 Result(s)

within P. Biron Remove this filter Internal Medicine Remove this filter

and

  1. No Access

    Article

    Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)

    This report retrospectively analyzed the outcome of 91 patients aged 60 years or older with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL) who underwent autologous stem cell transplantation (ASCT...

    A Stamatoullas, P Brice, M S Gueye, S Mareschal… in Bone Marrow Transplantation (2016)

  2. No Access

    Article

    The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT

    Both auto-SCT and reduced intensity allo-SCT (RIST) are employed in the treatment of relapsed follicular lymphoma (FL). We have analysed the outcome of these two transplant procedures when used as a first tran...

    S P Robinson, C Canals, J J Luang, H Tilly, C Crawley… in Bone Marrow Transplantation (2013)

  3. No Access

    Article

    Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer

    Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) a...

    P Biron, M Durand, H Roché, T Delozier, C Battista… in Bone Marrow Transplantation (2008)

  4. No Access

    Article

    A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma

    The potential benefit of rituximab as adjuvant to high-dose therapy (HDT) has been investigated in patients under 60 years with poor-risk (age-adjusted international prognostic index at 2–3) CD20+ diffuse larg...

    D Coso, C Sebban, O Boulat, P Biron, J Rey, T Aurran… in Bone Marrow Transplantation (2006)

  5. No Access

    Article

    High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)

    The most appropriate treatment for lymphoblastic lymphomas (LL) remains uncertain. We treated 27 patients with newly diagnosed LL according to an LMT-89 protocol, which is a modified version of the LMT-81 prot...

    E Jabbour, S Koscielny, C Sebban, N Peslin, C Patte, T Gargi, P Biron, C Fermé… in Leukemia (2006)

  6. No Access

    Article

    High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patients

    Between 1985 and 1996, 18 patients with diffuse centrocytic lymphoma (DCL), including nine patients with an established histological and phenotypic diagnosis of mantle cell lymphoma (MCL), received 19 courses ...

    J-Y Blay, C Sebban, C Surbiguet, M Ouachée, I Philip… in Bone Marrow Transplantation (1998)

  7. No Access

    Chapter

    Adrenocortical function in essential hypertension

    For the last 12 years, our main research work has been devoted to the study of the possible relationship of adrenocortical hormones and arterial hypertension in humans. Much clinical and experimental evidence,...

    J. Genest, W. Nowaczynski, E. Koiw, T. Sandor, P. Biron in Essential Hypertension (1960)